ERBB2 and breast carcinoma: This may indicate that in advanced HER2-positive breast cancer patients treated with lapatinib, phosphorylation of p-70S6K reflects significant activity of the Ras/Raf/MAPK pathway, particularly when accompanied by p-AMPK up-regulation.